Histologic and clinical evaluation for maxillary sinus augmentation using macroporous biphasic calcium phosphate in human.
OBJECTIVE
This study evaluated both the clinical and histological aspects of bone formation in maxillary sinus augmentation using MBCP as the bone-grafting material.


METHODS
MBCP was used as a primary bone substitute for maxillary sinus augmentation. Fifty-two patients were selected after a medical and dental examination, and were divided into the following three groups: those augmented with MBCP only; MBCP combined with irradiated cancellous bone; and MBCP combined with intraoral autogenous bone. After a healing period (average 6.78 months after surgery), bone cores were harvested for a histological evaluation and the implant fixtures were installed. These bone cores were evaluated via light microscope and implants were followed up for at least six months after loading.


RESULTS
Four to ten months after surgery, new vital bone surrounding the MBCP particles was observed in 18 bone biopsies. Two out of the 130 implants installed were explanted due to a failure of osseointegration before the prosthetic procedure. All the remaining implants were functioning for 6 to 27 months (average 12.96 months). The cumulative survival rate of the implants was 98.46%.


CONCLUSIONS
These results show that MBCP can be used as a grafting material for sinus floor augmentation, whether combined with other bone graft materials or not, and lead to a predictable prognosis for dental implants in the posterior maxillary area where there is insufficient vertical height for fixture installation.
Lee
Ji Hyun
JH
Department of Periodontology, Research Institute for Periodontal regeneration, College of Dentistry, Yonsei University, Seoul, South Korea.
Jung
Ui Won
UW
Kim
Chang Sung
CS
Choi
Seong Ho
SH
Cho
Kyoo Sung
KS
D000328:Adult; D000368:Aged; D016301:Alveolar Bone Loss / Q000473:pathology / Q000601:surgery*; D000540:Alveolar Ridge Augmentation / Q000379:methods*; D001672:Biocompatible Materials / Q000627:therapeutic use; D001857:Bone Matrix / Q000637:transplantation; D018786:Bone Substitutes / Q000627:therapeutic use*; D016025:Bone Transplantation / Q000379:methods*; D002130:Calcium Phosphates / Q000627:therapeutic use; D003758:Dental Implantation, Endosseous / Q000379:methods; D005260:Female; D006801:Humans; D008297:Male; D008437:Maxilla / Q000473:pathology / Q000601:surgery*; D008443:Maxillary Sinus / Q000473:pathology / Q000601:surgery; D008875:Middle Aged; D013516:Oral Surgical Procedures, Preprosthetic / Q000379:methods; D016348:Osseointegration / Q000187:drug effects / Q000502:physiology; D016896:Treatment Outcome
D001672:Biocompatible Materials; D018786:Bone Substitutes; D002130:Calcium Phosphates